Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
|Webinars|January 25, 2022
Optimizing the Payer/Provider Relationship for a Successful Annual Enrollment Period, Part 6
Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.
Advertisement
In the latest Matters in Managed Care webinar, experts discussed current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries. They discussed the health system, provider, and payer perspectives.
Steve Evans, MD, vice president for quality and utilization management, Intermountain Healthcare, moderated the panel with:
- Judith Ford, MD, medical director, Intermountain Healthcare
- Othella Ann Jurani-Suarez, MD, medical director, Intermountain Healthcare
- Kristine Gates, government program sales director, SelectHealth
- Matt Maher, senior sales manager, Humana
- Sherry Stanislaw, general manager, officer, SCAN Health Plan
In segment 6, they discussed the provider perspective.
Advertisement
Related to this article
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5